Article citationsMore >>

Yamamoto-Ibusuki M, Arnedos M, André F. Targeted therapies for ER+/HER2-metastatic breast cancer. BMC medicine. 2015 Jun 9; 13(1): 137.

has been cited by the following article:

Article

Oral Treatments in the Patients with Metastatic Breast Cancer - A Case Series

1Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran

2Department of Genetics, Shahid Sadoughi University of Medical Science, Yazd, Iran

3Department of Hematology, Shahid Beheshti University of Medical Sciences, Tehran, Iran


American Journal of Cancer Prevention. 2018, Vol. 6 No. 2, 29-31
DOI: 10.12691/ajcp-6-2-3
Copyright © 2018 Science and Education Publishing

Cite this paper:
Mehrdad Payandeh, Noorodin Karami, Afshin Karami, Mehrnoush Aeinfar, Fatemeh Feizi, Amir Yami. Oral Treatments in the Patients with Metastatic Breast Cancer - A Case Series. American Journal of Cancer Prevention. 2018; 6(2):29-31. doi: 10.12691/ajcp-6-2-3.

Correspondence to: Afshin  Karami, Department of Hematology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Email: afshinkarami72@gmail.com

Abstract

Breast cancer is one of the most common malignant diagnostic tumors among women and is considered as the second leading cause of mortality in them. Numerous approaches could be recruited for breast cancer management such as surgery, radiation therapy, endocrine, and chemotherapy. In past years, oncologists have prescribed intravenous anticancer drugs for many patients, but nowadays the issue of treatment has changed with the increasing use of oral anticancer drugs. Previous studies have shown that most patients prefer to take oral anticancer drugs and their main reason for this choice is the accessibility of home-based treatment. The objective of this issue was to evaluate the effects of oral therapy regimens such as palbociclib (Ibrance) in combination with aromatase inhibitors in patients with metastatic breast cancer. Our new remedies in the oral therapy field in 2 patients lead to control the progress of malignancy.

Keywords